Lawsone methyl ether
(Synonyms: 2-甲氧基-1,4-萘并醌,2-?Methoxy-?1,?4-?naphthoquinone) 目录号 : GC63825
2-Methoxy-1,4-naphthoquinone, isolated from the leaves of Impatiens glandulifera, specifically suppressed the expression of PKC βI, δ, and ζ in a concentration-dependent manner in Raji cells.
Cas No.:2348-82-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
2-Methoxy-1,4-naphthoquinone, isolated from the leaves of Impatiens glandulifera, specifically suppressed the expression of PKC βI, δ, and ζ in a concentration-dependent manner in Raji cells.
2-Methoxy-1,4-naphthoquinone (MNQ) exhibits antifungal, antimicrobial activities and showed strong killing effect on K562, HL-60, Raji, MCF-7, H-23, IMR-32, LA-174-T, HSC-2, and SK-MEL-28. MNQ is able to trigger the intrinsic apoptotic pathway in K562 cells, as well as causing p53-dependent cell cycle arrest in the p53-wild type cell line. MNQ inhibits the TCF/β-catenin (TOP) transcriptional activity at IC50 2.9 μM, while it decreases the transcriptional activity of FOP (mutated TCF-binding site)-transfected cell. MNQ exerts an anti-metastatic effect against MDA-MB-231 cells. MNQ has remarkable selectivity towards PKCβI and ζ suppression. MNQ suppresses PKCδ moderately, where MNQ suppresses half of the PKCδ expression at the concentration of 10 μM. MNQ does not suppress PKC βII[1]. MNQ is able to inhibit the invasion and migration characteristics of a highly metastatic MDA-MB-231 cancer cell line[2].
[1] Wong Teck Yew, et al. Journal of Applied Pharmaceutical Science. 2015, 5(08), pp001-005. [2] Liew K, et al. Toxicol In Vitro. 2014, 28(3):335-9.
| Cas No. | 2348-82-5 | SDF | Download SDF |
| 别名 | 2-甲氧基-1,4-萘并醌,2-?Methoxy-?1,?4-?naphthoquinone | ||
| 分子式 | C11H8O3 | 分子量 | 188.18 |
| 溶解度 | DMSO : 50 mg/mL (265.70 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.3141 mL | 26.5703 mL | 53.1406 mL |
| 5 mM | 1.0628 mL | 5.3141 mL | 10.6281 mL |
| 10 mM | 0.5314 mL | 2.657 mL | 5.3141 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet